Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,851.50    31.00 (1.70%)
Bid:
1,851.50
Ask:
1,852.00
Spread: 0.50 (0.027%)
Market Cap: £74.25b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

13 May 2025 15:30

RNS Number : 5056I
GSK PLC
13 May 2025
 

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Emma Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.5075

9 (partnership shares)

£13.5075

9 (matching shares)

d)

Aggregated information

 

 

Aggregated volume Price

18 Ordinary Shares

£13.5075

e)

Date of the transaction

2025-05-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Julie Brown

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.5075

10 (partnership shares)

£13.5075

10 (matching shares)

d)

Aggregated information

 

 

Aggregated volume Price

20 Ordinary Shares

£13.5075

e)

Date of the transaction

2025-05-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.5075

10 (partnership shares)

£13.5075

10 (matching shares)

d)

Aggregated information

 

 

Aggregated volume Price

20 Ordinary Shares

£13.5075

e)

Date of the transaction

2025-05-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sally Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.5075

9 (partnership shares)

£13.5075

9 (matching shares)

d)

Aggregated information

 

 

Aggregated volume Price

18 Ordinary Shares

£13.5075

e)

Date of the transaction

2025-05-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

President, Corporate Development

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.5075

10 (partnership shares)

£13.5075

10 (matching shares)

d)

Aggregated information

 

 

Aggregated volume Price

20 Ordinary Shares

£13.5075

e)

Date of the transaction

2025-05-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Regis Simard

b)

Position/status

President, Global Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.5075

9 (partnership shares)

£13.5075

9 (matching shares)

d)

Aggregated information

 

 

Aggregated volume Price

18 Ordinary Shares

£13.5075

e)

Date of the transaction

2025-05-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Philip Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.5075

9 (partnership shares)

£13.5075

9 (matching shares)

d)

Aggregated information

 

 

Aggregated volume Price

18 Ordinary Shares

£13.5075

e)

Date of the transaction

2025-05-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Deborah Waterhouse

b)

Position/status

CEO, ViiV Healthcare and President, Global Health, GSK

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.5075

9 (partnership shares)

£13.5075

9 (matching shares)

d)

Aggregated information

 

 

Aggregated volume Price

18 Ordinary Shares

£13.5075

e)

Date of the transaction

2025-05-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Victoria Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.5075

9 (partnership shares)

£13.5075

9 (matching shares)

d)

Aggregated information

 

 

Aggregated volume Price

18 Ordinary Shares

£13.5075

e)

Date of the transaction

2025-05-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFIFDDEISEII
Date   Source Headline
22nd Dec 20257:00 amRNSGSK to lower drug prices and expand access in US
22nd Dec 20257:00 amRNSGSK to lower drug prices and expand access in US
22nd Dec 20257:00 amRNSTransaction in Own Shares
22nd Dec 20257:00 amRNSTransaction in Own Shares
19th Dec 20257:00 amRNSTransaction in Own Shares
19th Dec 20257:00 amRNSTransaction in Own Shares
18th Dec 20257:00 amRNSTransaction in Own Shares
17th Dec 20257:00 amRNSExdensur (depemokimab ulla) approved by US FDA
17th Dec 20257:00 amRNSTransaction in Own Shares
16th Dec 20257:00 amRNSExdensur (depemokimab) UK MHRA approval
16th Dec 20257:00 amRNSTransaction in Own Shares
15th Dec 20257:00 amRNSTransaction in Own Shares
12th Dec 20251:50 pmRNSNucala receives positive CHMP opinion for COPD
12th Dec 20251:41 pmRNSDepemokimab receives positive CHMP opinion
12th Dec 20257:00 amRNSPositive CHMP opinion on Arexvy for all adults 18+
12th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:54 pmRNSBlujepa approved in US for gonorrhoea indication
11th Dec 20253:30 pmRNSDirector/PDMR Shareholding
11th Dec 20259:00 amRNSBlock Listing Application
11th Dec 20257:00 amRNSTransaction in Own Shares
10th Dec 20257:00 amRNSGSK'227 US FDA Orphan Drug Designation in SCLC
10th Dec 20257:00 amRNSTransaction in Own Shares
9th Dec 20253:30 pmRNSDirector/PDMR Shareholding
9th Dec 20257:00 amRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
5th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20257:00 amRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
2nd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20253:30 pmRNSDirector/PDMR Shareholding
1st Dec 20253:00 pmRNSTotal Voting Rights
1st Dec 20257:00 amRNSTransaction in Own Shares
28th Nov 20257:00 amRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSTransaction in Own Shares
25th Nov 20257:00 amRNSTransaction in Own Shares
24th Nov 20257:00 amRNSTransaction in Own Shares
21st Nov 20257:00 amRNSInitiation of litigation against AnaptysBio Inc
21st Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
19th Nov 20257:15 amRNSTransfer of Treasury Shares
19th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20253:30 pmRNSDirector/PDMR Shareholding
18th Nov 20257:00 amRNSTransaction in Own Shares
17th Nov 20257:00 amRNSTransaction in Own Shares
14th Nov 20257:00 amRNSTransaction in Own Shares
13th Nov 20253:30 pmRNSDirector/PDMR Shareholding
13th Nov 20257:00 amRNSTransaction in Own Shares
12th Nov 20253:30 pmRNSBlock listing Interim Review
12th Nov 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.